ABC | Volume 111, Nº2, Agosto 2018

Artigo Original Marino et al Cintilografia 123 I-MIBG na Insuficiência Cardíaca Arq Bras Cardiol. 2018; 111(2):182-190 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 30. Perkins A. Nuclear medicine: science and safety: London: John Libbey Company; 1995. 31. MontgomeryDC.DesignandAnalysisofExperiments.NewYork: JohnWiley & Sons; 1991. 32. Johnson RA, Bhattacharyya G. Statistics: principles andmethods: NewYork: John Wiley & Sons; 1987. 33. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86(6):656-60. 34. Stefanelli A, Treglia G, Bruno I, Rufini V, Giordano A. Pharmacological interferencewith123I-metaiodobenzylguanidine:a limitationtodeveloping cardiac innervation imaging in clinical practice? Eur RevMed Pharmacol Sci. 2013;17(10):1326-33. 35. Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, et al. Chagas heart disease: report on recent developments. Cardiol Rev. 2012;20(2):53-65. 36. RassiA Jr,RassiA,LittleWC,XavierSS,RassiSG,RassiAG,etal.Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med. 2006;355(8):799-808. 190